FY2022 · ended Dec 31, 2022 · Revenue $0, -100.0% YoY · Filed Mar 14, 2024
Cullinan Therapeutics, Inc. (CGEM) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$175.8 million. As of Jun 30, 2026 it held $353.6 million in cash and investments and $2.1 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-219.88M
-31.4% vs prior year
Operating cash flow (TTM)
$-159.25M
+7.2% vs year-ago TTM
Free cash flow
$-175.80M
-21.0% vs prior year
EPS
$-3.69
-255.0% vs prior year
Dividend per share
None
Shares outstanding
60.53M
+3.4% vs prior year
Net cash
$351.49M
as of Jun 30, 2026
Operating margin
-358.7%
FY 2021
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CGEM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1789972
- Former names
- Cullinan Oncology, Inc. (until Apr 2, 2024); Cullinan Management, Inc. (until Feb 22, 2021); Cullinan Oncology, LLC (until Jan 6, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $18.9M |
| Operating income | -$241.6M | -$196.9M | -$191.1M | $144.6M | -$68.0M |
| Net income | -$219.9M | -$167.4M | -$153.2M | $111.2M | -$65.6M |
| Diluted EPS | — | — | -$3.69 | $2.38 | — |
| Operating cash flow | -$175.8M | -$145.3M | -$134.3M | -$126.7M | -$43.4M |
| Free cash flow | -$175.8M | -$145.3M | -$134.5M | -$127.8M | — |
| Total assets | $448.4M | $621.8M | $484.2M | $561.1M | $437.2M |
| Total liabilities | $39.6M | $31.5M | $30.3M | $26.1M | $11.8M |
| Stockholders' equity | $408.7M | $590.3M | $453.7M | $535.0M | $425.0M |
| Cash and investments | $436.2M | $603.4M | $467.1M | $548.2M | $430.9M |
| Total debt | $2.7M | $2.2M | $3.6M | $5.0M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 2, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 24, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 13, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 465 Cullinan Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.